‘Something needs to change’: An Allergan analyst spells out why next week’s vote could still spark a major revamp

Just because ISS and Glass Lewis have thrown their weight behind Allergan CEO Brent Saunders in the upcoming shareholder vote at the annual meeting on Wednesday doesn’t mean that die-hard critics have put aside the manifestoes and helmets in preparation for a proper melee.